INIS
adults
6%
assessments
9%
barriers
5%
biological markers
9%
cancer
15%
comparative evaluations
17%
concentration
7%
control
15%
data
15%
diet
6%
diseases
70%
drugs
6%
genes
6%
glucose
6%
hepatitis
6%
hospitals
5%
humans
11%
inflammation
38%
intake
7%
interventions
9%
levels
16%
liver
25%
management
6%
metabolism
5%
monitoring
5%
mortality
5%
netherlands
8%
pain
6%
patients
100%
plasma
9%
populations
14%
quality of life
8%
receptors
5%
reviews
15%
risks
25%
safety
5%
screening
5%
sensitivity
5%
surgery
8%
symptoms
18%
therapy
10%
values
6%
women
5%
Keyphrases
Colorectal Cancer
5%
Confidence Interval
7%
Crohn's Disease
17%
Dutch
8%
Gastrointestinal Diseases
5%
Inflammatory Bowel Disease
29%
Irritable Bowel Syndrome
16%
Maastricht
15%
Netherlands
8%
Non-alcoholic Fatty Liver Disease (NAFLD)
7%
Quality of Life
5%
Randomized Controlled Trial
6%
Risk Factors
5%
Type 2 Diabetes Mellitus (T2DM)
11%
Ulcerative Colitis
5%
Medicine and Dentistry
Biological Marker
5%
Cohort Analysis
5%
Colonoscopy
5%
Colorectal Carcinoma
7%
Crohn's Disease
9%
Disease
10%
Inflammatory Bowel Disease
22%
Irritable Bowel Syndrome
12%
Maturity Onset Diabetes of the Young
10%
Nonalcoholic Fatty Liver
7%
Patient with Inflammatory Bowel Disease
6%
Quality of Life
9%
Randomized Controlled Trial
9%
Systematic Review
6%
Ulcerative Colitis
5%